TY - JOUR
T1 - Attemps to eradicate methicillin-resistant Staphylococcus aureus colonization with the use of trimethoprim-sulfamethoxazole, rafampin, and bacitracin
AU - Roccaforte, Jane S.
AU - Bittner, Marvin J.
AU - Stumpf, Carol A.
AU - Prehelm, Laurel C.
N1 - Funding Information:
Supported by the Veterans Administration.
PY - 1988/8
Y1 - 1988/8
N2 - Retrospective review of 197 patients with methicillin-resistant Staphylococcus aureus (MRSA) identified 47 in whom a regimen for eradication of MRSA colonization could be evaluated. The patients were elderly (mean age, 67.7 years), with 53% transferred from another institution and 53% treated in an intensive care unit. A mean of 47.1 days of hospitalization with an average of 4.9 antibiotics preceded the first MRSA culture. The usual regimen (mean, 6.0 days) was oral trimethoprimsulfamethoxazole, 160 800 mg twice daily, oral rifampin, 600 mg once daily, and bacitracin ointment three times a day. Eradication succeeded in 40 patients, 9 relapsed, and MRSA persisted in 7. Twenty-four of 25 nares sites were cleared but only 16 to 22 other sites. MRSA infection eventually developed in 36%. No adverse reactions to the eradication regimen were noted. Although this treatment for MRSA carriage was safe and effective, decreased efficacy outside the nares and relapse limited its value.
AB - Retrospective review of 197 patients with methicillin-resistant Staphylococcus aureus (MRSA) identified 47 in whom a regimen for eradication of MRSA colonization could be evaluated. The patients were elderly (mean age, 67.7 years), with 53% transferred from another institution and 53% treated in an intensive care unit. A mean of 47.1 days of hospitalization with an average of 4.9 antibiotics preceded the first MRSA culture. The usual regimen (mean, 6.0 days) was oral trimethoprimsulfamethoxazole, 160 800 mg twice daily, oral rifampin, 600 mg once daily, and bacitracin ointment three times a day. Eradication succeeded in 40 patients, 9 relapsed, and MRSA persisted in 7. Twenty-four of 25 nares sites were cleared but only 16 to 22 other sites. MRSA infection eventually developed in 36%. No adverse reactions to the eradication regimen were noted. Although this treatment for MRSA carriage was safe and effective, decreased efficacy outside the nares and relapse limited its value.
UR - http://www.scopus.com/inward/record.url?scp=0023811102&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023811102&partnerID=8YFLogxK
U2 - 10.1016/0196-6553(88)90024-7
DO - 10.1016/0196-6553(88)90024-7
M3 - Article
C2 - 3263821
AN - SCOPUS:0023811102
VL - 16
SP - 141
EP - 146
JO - American Journal of Infection Control
JF - American Journal of Infection Control
SN - 0196-6553
IS - 4
ER -